43 citations
,
November 2009 in “Archives of dermatology” Alefacept does not effectively treat severe alopecia areata.
January 2026 in “Acta Dermato Venereologica” Dupilumab effectively treats severe skin issues in a rare genetic disorder.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
37 citations
,
October 2014 in “JAMA dermatology” A woman with severe hair loss was successfully treated with the drug adalimumab.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
March 2025 in “Future Oncology” Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
April 2021 in “Journal of Investigative Dermatology” The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Mogamulizumab can cause hair loss, often linked to a better treatment response.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
15 citations
,
July 2010 in “Journal of Allergy and Clinical Immunology” A new cream, DHMEQ, reduces allergic skin inflammation effectively.
2 citations
,
December 2020 in “American Journal of Dermatological Research and Reviews” The combination therapy was effective and well-tolerated, especially in young patients.
53 citations
,
July 2009 in “Cancer Research” Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
253 citations
,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
July 2025 in “Ultrasound in Medicine & Biology” UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
50 citations
,
March 2021 in “Journal of investigational allergology & clinical immunology” Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
5 citations
,
May 2023 in “Clinical Rheumatology” Tofacitinib helped regrow hair in a lupus patient with alopecia.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
4 citations
,
May 2019 in “Sultan Qaboos University Medical Journal” Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
2 citations
,
January 2020 in “Einstein (São Paulo)” Topical tofacitinib shows promise as a future treatment for alopecia areata.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
July 2024 in “Journal of Investigative Dermatology” Biosimilars lower costs but don't significantly improve access.